Markets· August 17, 2026 at 03:49 p.m.
BDX Stock: Analysts Predict Mixed Outlook Amid Q3 Earnings Beat
Key takeaways
- BDX reported Q3 earnings that beat expectations
- The company expects full-year adjusted EPS in the range of $12.62 to $12.72
- Analysts have a 'Moderate Buy' consensus on BDX stock
Becton, Dickinson and Company (BDX), a global medical technology giant valued at $50.5 billion by market cap, reported its Q3 results on Aug. 6, with adjusted EPS of $3.23 beating Wall Street expectations of $3.14. The company's revenue was $5 billion, exceeding forecasts of $4.9 billion. Despite the positive earnings report, BDX has underperformed the broader market over the past year, gaining 19.6% compared to the S&P 500 Index's 20.4%. However, in 2026, BDX stock is up 20.2%, surpassing the SPX's 13.7% rise on a YTD basis. The company expects full-year adjusted EPS in the range of $12.62 to $12.72.
